Bristol-Myers Squibb, Pharmacyclics, Inc., and Janssen R&D, LLC have entered a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of BMS’ investigational PD-1 immune checkpoint inhibitor OPDIVO (nivolumab) in combination with IMBRUVICA (ibrutinib), an oral Bruton’s tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. Additional details were not disclosed. Janssen will conduct the Phase 1/2 study evaluating t...